NeoTX Therapeutics LTD Revenue and Competitors
Estimated Revenue & Valuation
- NeoTX Therapeutics LTD's estimated annual revenue is currently $5.3M per year.
- NeoTX Therapeutics LTD's estimated revenue per employee is $155,000
Employee Data
- NeoTX Therapeutics LTD has 34 Employees.
- NeoTX Therapeutics LTD grew their employee count by -15% last year.
NeoTX Therapeutics LTD's People
Name | Title | Email/Phone |
---|---|---|
1 | Executive Personal Assistant | Reveal Email/Phone |
NeoTX Therapeutics LTD Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is NeoTX Therapeutics LTD?
NeoTX is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy. With a strong research and development team, our strategy is to build a patented, proprietary and unique product pipeline to capitalize on technologies that NeoTX is developing independently and through collaborative partnerships and license agreements.
keywords:N/AN/A
Total Funding
34
Number of Employees
$5.3M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NeoTX Therapeutics LTD News
2022-04-19 - Active Biotech strengthens the patent protection for laquinimod in eye
disorders - Benzinga
(Limited Seating Event) ... Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.6M | 34 | 0% | N/A |
#2 | $4.2M | 36 | 6% | N/A |
#3 | $7.8M | 39 | -2% | N/A |
#4 | $8.8M | 45 | 2% | N/A |
#5 | $5.2M | 46 | -12% | N/A |